Roving Reporter Asks: How Is Cell and Gene Therapy Manufacturing Becoming More Scalable? - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Roving Reporter Asks: How Is Cell and Gene Therapy Manufacturing Becoming More Scalable?

IBTV speaks with industry leaders at ASGCT 2026 about the technologies, processes, and manufacturing strategies helping advanced therapies progress toward commercial scale

  • September 18, 2026

  • 2 min

Share

  • 1

    Manufacturing challenges hinder the widespread adoption of cell and gene therapies.

  • 2

    Stable cell lines and process intensification are key to improving manufacturing scalability.

  • 3

    AI-driven process modeling and quality-by-design enhance output while ensuring product quality.

  • 4

    Flexible manufacturing models and advanced analytical technologies support diverse therapeutic needs.

  • 5

    Regulatory flexibility and data-led process control are crucial for large-scale commercialization.

Original Source(s)

Roving Reporter Asks: How Is Cell and Gene Therapy Manufacturing Becoming More Scalable?

  • September 18, 2026

Related Content

Current status and future directions of AI in prostate cancer detection on MRI: a special report from the ESUR prostate MRI working group authors

The Pitfalls of Disproportionality Analysis: Insights on Their Interwoven Complexity and a Front-End Mitigation Strategy

Musings from The Power List: Dajun Yang

The Ascentage Pharma CEO on why next-generation small molecules are expanding into territory once reserved for biologics

  • September 15, 2026

  • 5 min